Table 3 Median Fridericia corrected QT interval (QTcF) and proportion with abnormal ECG findings from baseline to last day of dosing among participants on artemether–lumefantrine and efavirenz-based antiretroviral therapy in the intention-to-treat population (N = 152)
Median (IQR) QTcF in msec | Proportion with QTcF ≥ 450 ms | Proportion with QTcF change > 60 ms from baseline to last day of dosing on day 2 (taken within 2 h of dosing) | |
|---|---|---|---|
Time of ECG test | NA | n (%) | n (%) |
Day 0 | 393 (358–413) | 6 (3.9) | NA |
Day 1 | 392 (358–413) | 6 (3.9) | 19 (12.3) |
Day 2 | 384 (359–402) | 1 (0.7) | 26 (17.1) |
Follow-up visit after day 2 (day 7 or 14 of follow up) | 392 (384–436) | 0 | NA |